A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide
The antibiotic pyrazinamide is central to tuberculosis treatment regimens, globally. Despite its efficacy, resistance to the drug is increasing. Here, Eric Rubin and colleagues characterise the genetic basis of pyrazinamide resistance.
Guardado en:
Autores principales: | Adam N. Yadon, Kashmeel Maharaj, John H. Adamson, Yi-Pin Lai, James C. Sacchettini, Thomas R. Ioerger, Eric J. Rubin, Alexander S. Pym |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/64b393ee6e854aef8a3dc9823de250ff |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Author Correction: Analysis of mutations in pncA reveals non-overlapping patterns among various lineages of Mycobacterium tuberculosis
por: Ramani Baddam, et al.
Publicado: (2018) -
The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD
por: Qingan Sun, et al.
Publicado: (2020) -
Pyrazinamide triggers degradation of its target aspartate decarboxylase
por: Pooja Gopal, et al.
Publicado: (2020) -
EFFECTS OF PYRAZINAMIDE ON PREGNANT ALBINO RATS
por: Pascale Quintino,Marisa, et al.
Publicado: (2003) -
Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide
por: Pierre Santucci, et al.
Publicado: (2021)